The diagnostic laboratory industry is escalating its advocacy efforts on Capitol Hill following the release of a new preliminary Medicare payment schedule that threatens to impose the maximum allowable cuts on hundreds of essential medical tests. The Centers for Medicare and Medicaid Services (CMS) recently unveiled the 2027 Clinical Laboratory Fee Schedule (CLFS), a move that has reignited a long-standing battle over how the federal government calculates reimbursement rates for services ranging from routine blood work to advanced genetic screenings. Under the proposed schedule, nearly 1,200 laboratory tests face payment reductions, with 775 of those tests slated for a 15% decrease—the maximum cut permitted under current law.
This development has mobilized a broad coalition of healthcare stakeholders, including the American Clinical Laboratory Association (ACLA), the American Hospital Association (AHA), and industry giants like Quest Diagnostics and Labcorp. These organizations are urging Congress to intervene by passing the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act. The legislation aims to overhaul the data collection methodology established by the Protecting Access to Medicare Act (PAMA) of 2014, which critics argue relies on a flawed and unrepresentative sample of the commercial market.
The Origins of the PAMA Framework and Current Rate-Setting Flaws
The current tension traces back to the passage of PAMA in 2014. The law was intended to modernize Medicare’s payment system by aligning reimbursement rates with those paid by private insurers. To achieve this, PAMA required laboratories to report their private payer data to CMS every three years. The agency would then use the weighted median of these rates to set the Medicare fee schedule.
However, the implementation of PAMA has been a point of contention for a decade. Industry leaders argue that the data collection process is inherently skewed. Because the reporting requirements are administratively burdensome, the vast majority of data submitted to CMS has come from large national independent laboratories that benefit from economies of scale and often accept lower rates. Conversely, thousands of hospital-based laboratories and physician office laboratories, which often have higher operating costs and different negotiated rates, have been largely excluded from the data set.
According to the ACLA, the current methodology creates a "downward spiral" that does not reflect the true cost of providing diagnostic services across the diverse American healthcare landscape. The 15% cuts proposed for 2027 represent the statutory cap for annual reductions, a limit designed to prevent total market collapse, but one that industry experts say still poses a grave threat to the sustainability of many testing facilities.
The RESULTS Act: A Proposed Long-Term Solution
In response to the perceived failures of PAMA, the RESULTS Act has emerged as the primary legislative vehicle for reform. Unlike the current system, which relies on laboratories to self-report complex data sets, the RESULTS Act would mandate that CMS utilize a more comprehensive and statistically valid approach.
The bill proposes that CMS contract with an independent, not-for-profit commercial claims database to gather pricing information. This would theoretically capture a much broader and more representative slice of the market, including data from rural hospitals, community clinics, and specialized pathology practices. Quest Diagnostics CEO James Davis recently emphasized the urgency of this transition, stating that the RESULTS Act provides a "sensible and fair" alternative to the "incomplete and skewed" process currently in place.
The legislation has garnered significant bipartisan interest and the endorsement of major medical organizations. The American Medical Association (AMA) and the American Cancer Society have joined laboratory providers in supporting the bill, arguing that the stability of the nation’s diagnostic infrastructure is essential for early disease detection and chronic disease management.
Analyzing the Impact: $1 Billion in Savings vs. Patient Access
The federal government’s perspective on these cuts is rooted in fiscal responsibility and the mandate to protect the Medicare Trust Fund. CMS Administrator Dr. Mehmet Oz recently defended the proposed adjustments, noting that the new rates are expected to save the government approximately $1 billion annually. Dr. Oz asserted that for too long, taxpayers and Medicare beneficiaries have paid rates significantly higher than those found in the private sector for identical services.
"Taxpayers and Medicare patients have been paying excessive rates to labs for years," Dr. Oz stated during the announcement of the preliminary schedule. "CMS is working to ensure that Medicare isn’t paying more than private insurers for the exact same tests."
However, laboratory providers warn that these savings come at a high price for patient care. Qihui "Jim" Zhai, President of the College of American Pathologists (CAP), warned that cuts of this magnitude threaten the very stability of the laboratory infrastructure. The concern is particularly acute for rural and underserved areas, where the margin for operating a laboratory is razor-thin. If reimbursement rates fall below the cost of performance, these facilities may be forced to consolidate or shutter, leading to longer turnaround times for results and reduced access for patients.
Chronology of Legislative Delays and the Path Forward
The battle over PAMA cuts is not a new phenomenon. Since the first round of cuts was implemented in 2018, Congress has stepped in on multiple occasions to delay further reductions. These "punts," as they are often called in Washington, have provided temporary relief but have failed to address the underlying structural issues of the law.
- 2014: PAMA is signed into law, establishing the market-based payment system.
- 2018: The first round of significant cuts takes effect, leading to immediate industry backlash.
- 2020–2023: Recognizing the strain on the healthcare system during the COVID-19 pandemic, Congress passes several pieces of legislation (including the CARES Act and subsequent year-end spending bills) to delay further PAMA cuts and reporting periods.
- 2024: The RESULTS Act is introduced in the House and Senate, gaining momentum as the latest temporary delay nears its expiration.
- Late 2024: CMS releases the preliminary 2027 fee schedule, signaling that without legislative intervention, the 15% cuts will proceed.
Currently, the House of Representatives is in recess until after the November midterm elections. This timing complicates the industry’s push for the RESULTS Act, as the window for legislative action in the "lame-duck" session following the election is notoriously narrow. Nevertheless, proponents of the bill are hopeful that it can be tucked into a larger, must-pass year-end healthcare or omnibus spending package.
Economic Implications for Industry Leaders
For major players like Labcorp and Quest Diagnostics, the proposed cuts represent a significant headwind, though one they have been navigating for years. In recent securities filings, Labcorp reaffirmed its long-term financial forecasts, noting that its projections already account for ongoing reimbursement pressure related to PAMA.
Despite their ability to absorb some of these shocks through diversified business models—such as clinical trial support and drug development services—these companies maintain that the Medicare cuts are counterproductive to the goal of advancing precision medicine. Advanced diagnostic tests, which are crucial for tailoring treatments to individual genetic profiles, are among the services most vulnerable to price volatility under the current CMS methodology.
The industry argues that if Medicare rates are set too low, it disincentivizes investment in new testing technologies. "The current payment system is not sustainable," Zhai noted, echoing the sentiment that the 2027 schedule could stifle innovation in a field that is increasingly central to modern healthcare.
The Broader Healthcare Context
The debate over laboratory reimbursement does not exist in a vacuum. It is part of a larger national conversation regarding the rising cost of healthcare and the move toward value-based care. While CMS is focused on immediate cost-savings, the laboratory industry argues that diagnostic testing is one of the most cost-effective components of the healthcare continuum. Laboratory tests account for only about 2% of total Medicare spending but influence approximately 70% of medical decisions.
If the cuts proceed, the ripple effects could be felt across various medical specialties. For instance, oncology relies heavily on frequent blood work and molecular testing to monitor the efficacy of chemotherapy. Similarly, the management of diabetes and cardiovascular disease depends on routine screenings that are now targeted for the 15% reduction.
Future Outlook and Market Predictions
Financial analysts at TD Cowen and other firms remain cautiously optimistic that another delay is on the horizon. History suggests that when faced with the prospect of significant disruptions to patient care, lawmakers often opt for a temporary extension of the status quo. "We continue to think it is most likely that Congress will punt the 2027 PAMA cuts like it has done in previous years," analysts wrote in a recent note to investors.
However, the industry is no longer satisfied with temporary fixes. The push for the RESULTS Act represents a desire for "permanent payment reform" that would end the cycle of annual lobbying and uncertainty. As the end of the year approaches, the focus will shift to the post-election legislative landscape, where the fate of the RESULTS Act—and the stability of the nation’s diagnostic laboratories—will likely be decided.
For now, laboratories must operate under the shadow of the proposed 2027 schedule, balancing the need for continued investment in testing capacity with the reality of a potentially shrinking reimbursement pool. Whether through the passage of the RESULTS Act or another last-minute congressional intervention, the resolution of this conflict will have lasting implications for the economics of American healthcare and the accessibility of diagnostic services for millions of Medicare beneficiaries.
